Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Let’s keep the information as real as we can…why not

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Apr 23, 2023 11:38am

106 Views

Post# 35409309

RE:Let’s keep the information as real as we can…why not

We need P3 or double P3 to see the SP explod! You are rehashing the same comments over and over but in the end you are not going to see a buyout in billions without P3 and a share price moving accordignily before. Will be happy to be proven wrong of course! GL

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders